Sociodemographic status (SDS) risk adjustment is changing how medication adherence is measured in Medicare Advantage. Starting in 2026, CMS will adjust adherence scores based on sociodemographic factors. This shift recognizes a simple reality. Patients do not all face the same barriers to taking their medications. The change brings new opportunity and new responsibility for organizations focused on value-based care.
In practice, SDS means adherence performance will account for factors such as age, disability status, and whether a patient qualifies for low-income subsidy or dual eligibility. These factors have a real impact on medication access, follow-through, and consistency.
This update aims to create fairer comparisons across plans and provider groups. It also raises the bar for how well organizations understand and support their patient populations.
When SDS Risk Adjustment Takes Effect
The timing of SDS risk adjustment matters. In measurement year 2026, which impacts 2028 Star Ratings, SDS-adjusted adherence measures will be included at a 1x weighting. This lowers the immediate impact on overall Star performance.
In measurement year 2027, which impacts 2029 Star Ratings, those same adherence measures return to 3x weighting. The change is not gradual. It snaps back to full weight.
This means 2026 is not a pause year. It is a preparation year.
If organizations do not adapt to SDS-adjusted adherence now, they risk a sudden drop in Star Ratings and bonus revenue when 3× weighting returns, with little time to recover in 2029. The most urgent risk is misreading SDS as forgiveness, which will leave them underperforming peers with similar populations and facing financial and contract consequences just as scrutiny increases.
Whereas organizations that use this time to strengthen adherence workflows will be better positioned when triple weighting returns. Those that slow down risk falling behind just as the stakes increase.
Why Adherence Still Deserves Focus
Medication adherence remains one of the strongest drivers of patient outcomes. Patients who take medications as prescribed are healthier. They experience fewer complications. They avoid unnecessary hospital visits.
Adherence also supports performance beyond a single metric. It stabilizes quality scores. It strengthens patient trust. It improves retention.
SDS risk adjustment does not reduce the importance of adherence. It changes how performance is evaluated. That distinction matters.
Strong strategies go beyond reminders by identifying barriers early and connecting pharmacy data, clinical insight, and care team action, then focusing support where patients struggle most, whether that is cost, transportation, education, or follow-up.
This level of precision requires clear workflows and reliable data. It also requires teams who understand why adherence breaks down in real life.
Preparing for SDS Risk Adjustment with Confidence
At VBC Transformation Partners, we help organizations turn regulatory changes into strategic advantage. We help practices and groups understand their patient mix, assess adherence risk, and build practical systems that support patients and care teams.
SDS risk adjustment is not just a scoring update. It is a signal. CMS is asking the industry to measure performance with more context and more fairness.
If you want to talk through how SDS risk adjustment affects your adherence strategy, now is the right time. Let’s connect and discuss a plan that supports your patients today and protects your performance tomorrow.
